| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Opioid-Related Disorders | 76 | 2024 | 465 | 17.330 |
Why?
|
| Substance-Related Disorders | 80 | 2025 | 691 | 11.670 |
Why?
|
| Buprenorphine | 32 | 2024 | 186 | 9.070 |
Why?
|
| Narcotic Antagonists | 28 | 2024 | 114 | 6.750 |
Why?
|
| Substance Abuse Treatment Centers | 34 | 2019 | 103 | 6.360 |
Why?
|
| Opiate Substitution Treatment | 34 | 2024 | 192 | 6.300 |
Why?
|
| Prisoners | 31 | 2024 | 166 | 5.800 |
Why?
|
| Drug Overdose | 18 | 2025 | 120 | 5.580 |
Why?
|
| Naltrexone | 21 | 2024 | 75 | 5.390 |
Why?
|
| Substance Abuse, Intravenous | 28 | 2024 | 75 | 4.790 |
Why?
|
| Rural Population | 17 | 2025 | 191 | 4.010 |
Why?
|
| Alcoholism | 20 | 2022 | 307 | 3.840 |
Why?
|
| Analgesics, Opioid | 25 | 2024 | 496 | 3.740 |
Why?
|
| Hepatitis C | 9 | 2024 | 139 | 3.730 |
Why?
|
| HIV Infections | 22 | 2025 | 921 | 3.580 |
Why?
|
| Methadone | 29 | 2024 | 126 | 3.440 |
Why?
|
| Patient Protection and Affordable Care Act | 10 | 2019 | 46 | 3.230 |
Why?
|
| Medicaid | 10 | 2025 | 335 | 3.000 |
Why?
|
| Health Services Accessibility | 16 | 2025 | 542 | 2.820 |
Why?
|
| Humans | 265 | 2025 | 59495 | 2.810 |
Why?
|
| Adult | 128 | 2025 | 15783 | 2.380 |
Why?
|
| Insurance Coverage | 8 | 2025 | 98 | 2.380 |
Why?
|
| United States | 79 | 2025 | 7511 | 2.380 |
Why?
|
| Criminal Law | 9 | 2018 | 91 | 2.230 |
Why?
|
| Male | 156 | 2025 | 27562 | 1.970 |
Why?
|
| Female | 155 | 2025 | 30908 | 1.950 |
Why?
|
| Patient Acceptance of Health Care | 11 | 2025 | 446 | 1.860 |
Why?
|
| Prisons | 12 | 2024 | 114 | 1.790 |
Why?
|
| Delayed-Action Preparations | 11 | 2024 | 105 | 1.720 |
Why?
|
| Health Policy | 5 | 2024 | 185 | 1.710 |
Why?
|
| Alcohol Drinking | 11 | 2022 | 299 | 1.690 |
Why?
|
| Patient-Centered Care | 4 | 2020 | 248 | 1.590 |
Why?
|
| Neonatal Abstinence Syndrome | 4 | 2020 | 33 | 1.570 |
Why?
|
| Primary Health Care | 14 | 2017 | 647 | 1.540 |
Why?
|
| Ambulatory Care | 11 | 2021 | 300 | 1.500 |
Why?
|
| Needle-Exchange Programs | 10 | 2024 | 15 | 1.420 |
Why?
|
| Drug Users | 7 | 2025 | 28 | 1.380 |
Why?
|
| Needle Sharing | 6 | 2024 | 13 | 1.370 |
Why?
|
| Emergency Service, Hospital | 9 | 2022 | 1023 | 1.360 |
Why?
|
| Criminals | 7 | 2018 | 59 | 1.320 |
Why?
|
| Secondary Prevention | 9 | 2017 | 153 | 1.300 |
Why?
|
| Middle Aged | 74 | 2025 | 16275 | 1.300 |
Why?
|
| State Government | 3 | 2019 | 32 | 1.280 |
Why?
|
| Continuity of Patient Care | 6 | 2017 | 172 | 1.240 |
Why?
|
| Mass Screening | 11 | 2023 | 647 | 1.230 |
Why?
|
| Practice Patterns, Physicians' | 8 | 2023 | 715 | 1.220 |
Why?
|
| Narcotics | 7 | 2012 | 50 | 1.210 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2015 | 114 | 1.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 9 | 2024 | 741 | 1.110 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2024 | 117 | 1.070 |
Why?
|
| Cataract Extraction | 3 | 2011 | 35 | 1.070 |
Why?
|
| Massachusetts | 18 | 2024 | 2086 | 1.060 |
Why?
|
| Telemedicine | 2 | 2024 | 335 | 1.030 |
Why?
|
| Qualitative Research | 9 | 2024 | 609 | 1.010 |
Why?
|
| Cross-Sectional Studies | 26 | 2024 | 2468 | 1.010 |
Why?
|
| Hepacivirus | 5 | 2024 | 140 | 1.010 |
Why?
|
| Referral and Consultation | 8 | 2024 | 409 | 1.000 |
Why?
|
| New England | 9 | 2024 | 268 | 0.980 |
Why?
|
| Medication Adherence | 2 | 2017 | 255 | 0.970 |
Why?
|
| Postoperative Complications | 8 | 2011 | 1134 | 0.960 |
Why?
|
| Attitude of Health Personnel | 8 | 2024 | 558 | 0.950 |
Why?
|
| Delivery of Health Care | 4 | 2020 | 421 | 0.950 |
Why?
|
| Mothers | 6 | 2023 | 261 | 0.920 |
Why?
|
| Recidivism | 2 | 2022 | 26 | 0.910 |
Why?
|
| Behavior, Addictive | 3 | 2014 | 75 | 0.900 |
Why?
|
| Fentanyl | 1 | 2024 | 70 | 0.890 |
Why?
|
| Sexual Partners | 5 | 2013 | 74 | 0.850 |
Why?
|
| Early Medical Intervention | 2 | 2020 | 17 | 0.850 |
Why?
|
| Surveys and Questionnaires | 23 | 2023 | 2592 | 0.850 |
Why?
|
| Health Services Needs and Demand | 9 | 2015 | 214 | 0.840 |
Why?
|
| Behavior Therapy | 3 | 2016 | 161 | 0.840 |
Why?
|
| Pharmacies | 1 | 2023 | 36 | 0.820 |
Why?
|
| Population Surveillance | 3 | 2019 | 205 | 0.790 |
Why?
|
| Counseling | 8 | 2021 | 351 | 0.780 |
Why?
|
| Inservice Training | 2 | 2017 | 83 | 0.780 |
Why?
|
| Smoking Cessation | 7 | 2016 | 531 | 0.780 |
Why?
|
| Harm Reduction | 3 | 2024 | 24 | 0.770 |
Why?
|
| Injections, Intramuscular | 6 | 2020 | 69 | 0.770 |
Why?
|
| Drug Monitoring | 2 | 2012 | 99 | 0.750 |
Why?
|
| Naloxone | 6 | 2023 | 54 | 0.750 |
Why?
|
| Substance Abuse Detection | 5 | 2009 | 39 | 0.740 |
Why?
|
| Tobacco Use Disorder | 4 | 2014 | 245 | 0.730 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 26 | 0.720 |
Why?
|
| Sexual Behavior | 8 | 2025 | 183 | 0.710 |
Why?
|
| Sleep Wake Disorders | 3 | 2008 | 68 | 0.700 |
Why?
|
| Interinstitutional Relations | 2 | 2016 | 40 | 0.700 |
Why?
|
| Intraoperative Complications | 2 | 2011 | 81 | 0.700 |
Why?
|
| Alcohol-Related Disorders | 3 | 2021 | 36 | 0.690 |
Why?
|
| Healthcare Disparities | 3 | 2024 | 330 | 0.680 |
Why?
|
| Parents | 2 | 2023 | 379 | 0.680 |
Why?
|
| Infant Health | 1 | 2019 | 2 | 0.670 |
Why?
|
| Maternal Health | 1 | 2019 | 13 | 0.660 |
Why?
|
| Surgical Procedures, Operative | 3 | 2012 | 139 | 0.660 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 73 | 0.660 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2019 | 19 | 0.650 |
Why?
|
| Hospitalization | 7 | 2024 | 1282 | 0.650 |
Why?
|
| Patient Dropouts | 5 | 2007 | 48 | 0.640 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2019 | 4 | 0.640 |
Why?
|
| Epidemics | 1 | 2019 | 22 | 0.640 |
Why?
|
| Family Practice | 7 | 2005 | 204 | 0.640 |
Why?
|
| Financing, Government | 1 | 2019 | 33 | 0.640 |
Why?
|
| Young Adult | 16 | 2024 | 4329 | 0.630 |
Why?
|
| Fear | 3 | 2024 | 64 | 0.620 |
Why?
|
| HIV Seropositivity | 7 | 2012 | 82 | 0.620 |
Why?
|
| Community Health Services | 4 | 2016 | 128 | 0.620 |
Why?
|
| Veterans | 7 | 2014 | 723 | 0.610 |
Why?
|
| Health Status | 5 | 2022 | 449 | 0.610 |
Why?
|
| Government Programs | 1 | 2017 | 20 | 0.590 |
Why?
|
| Cooperative Behavior | 4 | 2024 | 220 | 0.580 |
Why?
|
| Rhode Island | 10 | 2013 | 97 | 0.580 |
Why?
|
| Heroin Dependence | 5 | 2012 | 22 | 0.580 |
Why?
|
| Models, Statistical | 3 | 2016 | 306 | 0.580 |
Why?
|
| Multivariate Analysis | 13 | 2024 | 926 | 0.580 |
Why?
|
| Quality of Life | 5 | 2020 | 1116 | 0.570 |
Why?
|
| Aged | 40 | 2024 | 13339 | 0.570 |
Why?
|
| General Surgery | 5 | 2001 | 186 | 0.560 |
Why?
|
| Quality Assurance, Health Care | 2 | 2016 | 246 | 0.560 |
Why?
|
| Patient Compliance | 7 | 2018 | 372 | 0.550 |
Why?
|
| Informed Consent | 5 | 2018 | 133 | 0.550 |
Why?
|
| Retrospective Studies | 21 | 2024 | 6008 | 0.540 |
Why?
|
| Politics | 1 | 2017 | 31 | 0.540 |
Why?
|
| Law Enforcement | 2 | 2013 | 27 | 0.540 |
Why?
|
| Public Health | 2 | 2017 | 180 | 0.530 |
Why?
|
| Data Collection | 12 | 2023 | 384 | 0.530 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 5089 | 0.520 |
Why?
|
| Pharmacists | 3 | 2013 | 123 | 0.520 |
Why?
|
| Health Resources | 1 | 2016 | 88 | 0.520 |
Why?
|
| Anti-Anxiety Agents | 2 | 2008 | 31 | 0.520 |
Why?
|
| Crime | 3 | 2012 | 63 | 0.510 |
Why?
|
| Treatment Outcome | 18 | 2024 | 5183 | 0.510 |
Why?
|
| Police | 1 | 2016 | 37 | 0.500 |
Why?
|
| Hepatitis C, Chronic | 2 | 2013 | 88 | 0.500 |
Why?
|
| State Health Plans | 1 | 2015 | 12 | 0.490 |
Why?
|
| Resource Allocation | 1 | 2015 | 20 | 0.490 |
Why?
|
| Health Care Rationing | 1 | 2015 | 21 | 0.490 |
Why?
|
| Social Stigma | 7 | 2025 | 67 | 0.490 |
Why?
|
| Prescriptions | 1 | 2015 | 33 | 0.490 |
Why?
|
| Health Plan Implementation | 1 | 2015 | 42 | 0.480 |
Why?
|
| Cohort Studies | 18 | 2024 | 2442 | 0.480 |
Why?
|
| Longitudinal Studies | 10 | 2017 | 1225 | 0.480 |
Why?
|
| Mental Health Services | 7 | 2020 | 299 | 0.480 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 79 | 0.470 |
Why?
|
| Community Mental Health Services | 1 | 2016 | 104 | 0.470 |
Why?
|
| Hindlimb | 4 | 2000 | 44 | 0.460 |
Why?
|
| Mental Disorders | 7 | 2019 | 764 | 0.450 |
Why?
|
| Evidence-Based Medicine | 3 | 2013 | 452 | 0.450 |
Why?
|
| Blood Loss, Surgical | 2 | 2012 | 55 | 0.450 |
Why?
|
| Syringes | 2 | 2024 | 11 | 0.450 |
Why?
|
| Directly Observed Therapy | 1 | 2013 | 3 | 0.440 |
Why?
|
| Fibroblast Growth Factor 2 | 3 | 2000 | 17 | 0.440 |
Why?
|
| HIV Seronegativity | 4 | 2002 | 18 | 0.440 |
Why?
|
| Prevalence | 11 | 2024 | 1281 | 0.430 |
Why?
|
| Pharmaceutical Services | 2 | 2013 | 31 | 0.430 |
Why?
|
| Physicians, Family | 5 | 2008 | 75 | 0.430 |
Why?
|
| Interviews as Topic | 8 | 2024 | 486 | 0.430 |
Why?
|
| Adolescent | 16 | 2023 | 5930 | 0.430 |
Why?
|
| Patient Satisfaction | 3 | 2008 | 410 | 0.420 |
Why?
|
| Methamphetamine | 2 | 2023 | 22 | 0.420 |
Why?
|
| Prescription Drug Misuse | 1 | 2013 | 22 | 0.420 |
Why?
|
| Blood Transfusion | 2 | 2012 | 148 | 0.420 |
Why?
|
| Internet | 2 | 2015 | 458 | 0.420 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2012 | 9 | 0.410 |
Why?
|
| Pilot Projects | 6 | 2022 | 919 | 0.410 |
Why?
|
| Infant | 5 | 2021 | 1527 | 0.410 |
Why?
|
| Residential Treatment | 3 | 2024 | 35 | 0.410 |
Why?
|
| Needles | 1 | 2013 | 63 | 0.400 |
Why?
|
| Risk-Taking | 10 | 2025 | 160 | 0.400 |
Why?
|
| Cardiovascular Diseases | 7 | 2022 | 827 | 0.400 |
Why?
|
| Health Personnel | 1 | 2016 | 341 | 0.400 |
Why?
|
| Length of Stay | 5 | 2007 | 771 | 0.390 |
Why?
|
| Prospective Studies | 15 | 2020 | 3101 | 0.390 |
Why?
|
| Age Factors | 5 | 2017 | 1518 | 0.390 |
Why?
|
| Logistic Models | 11 | 2019 | 1252 | 0.390 |
Why?
|
| Hematocrit | 2 | 2010 | 33 | 0.370 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2012 | 93 | 0.370 |
Why?
|
| Antiviral Agents | 3 | 2024 | 314 | 0.360 |
Why?
|
| Prescription Drugs | 1 | 2011 | 50 | 0.360 |
Why?
|
| Eye Diseases | 1 | 2011 | 37 | 0.360 |
Why?
|
| Comorbidity | 8 | 2019 | 1090 | 0.360 |
Why?
|
| Chronic Disease | 3 | 2010 | 735 | 0.360 |
Why?
|
| Intraoperative Care | 1 | 2010 | 36 | 0.350 |
Why?
|
| Pregnancy | 7 | 2021 | 2355 | 0.350 |
Why?
|
| Rectal Neoplasms | 5 | 1996 | 97 | 0.340 |
Why?
|
| Alcoholic Intoxication | 2 | 2017 | 27 | 0.330 |
Why?
|
| Internship and Residency | 7 | 2002 | 723 | 0.330 |
Why?
|
| Infant, Newborn | 6 | 2020 | 1311 | 0.330 |
Why?
|
| Violence | 2 | 2009 | 149 | 0.330 |
Why?
|
| Practice Guidelines as Topic | 5 | 2014 | 703 | 0.330 |
Why?
|
| Quality of Health Care | 4 | 2012 | 519 | 0.320 |
Why?
|
| Influenza Vaccines | 2 | 2014 | 88 | 0.320 |
Why?
|
| Leadership | 2 | 2023 | 201 | 0.320 |
Why?
|
| Patient Care Team | 2 | 2024 | 327 | 0.320 |
Why?
|
| Psychiatry | 3 | 2005 | 129 | 0.320 |
Why?
|
| Neovascularization, Physiologic | 2 | 2000 | 102 | 0.320 |
Why?
|
| Trazodone | 1 | 2008 | 3 | 0.310 |
Why?
|
| Databases, Factual | 4 | 2019 | 838 | 0.310 |
Why?
|
| Child, Preschool | 5 | 2023 | 1839 | 0.310 |
Why?
|
| Recurrence | 5 | 2017 | 578 | 0.310 |
Why?
|
| Inpatients | 2 | 2024 | 296 | 0.300 |
Why?
|
| Evidence-Based Practice | 2 | 2023 | 82 | 0.300 |
Why?
|
| Health Care Surveys | 7 | 2013 | 279 | 0.300 |
Why?
|
| Education, Medical, Continuing | 2 | 2006 | 98 | 0.300 |
Why?
|
| Central Nervous System Depressants | 1 | 2008 | 42 | 0.300 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2008 | 17 | 0.300 |
Why?
|
| Regression Analysis | 8 | 2011 | 484 | 0.290 |
Why?
|
| Time Factors | 10 | 2017 | 3579 | 0.290 |
Why?
|
| Polycythemia | 1 | 2007 | 4 | 0.290 |
Why?
|
| Health Care Reform | 2 | 2019 | 88 | 0.290 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2022 | 668 | 0.280 |
Why?
|
| Program Evaluation | 5 | 2019 | 484 | 0.280 |
Why?
|
| Meningitis | 2 | 1998 | 18 | 0.280 |
Why?
|
| Ischemia | 4 | 2000 | 192 | 0.280 |
Why?
|
| Social Work | 2 | 2024 | 24 | 0.270 |
Why?
|
| Hallucinogens | 1 | 2006 | 14 | 0.270 |
Why?
|
| Outpatients | 3 | 2017 | 131 | 0.270 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2006 | 18 | 0.270 |
Why?
|
| Follow-Up Studies | 12 | 2017 | 2329 | 0.270 |
Why?
|
| Social Security | 1 | 2006 | 7 | 0.260 |
Why?
|
| Oxycodone | 1 | 2006 | 32 | 0.260 |
Why?
|
| Pregnancy Complications | 3 | 2019 | 391 | 0.260 |
Why?
|
| Antidepressive Agents | 2 | 2010 | 229 | 0.260 |
Why?
|
| Preventive Health Services | 3 | 2012 | 72 | 0.260 |
Why?
|
| Anemia | 1 | 2007 | 117 | 0.260 |
Why?
|
| Case Management | 2 | 2004 | 61 | 0.260 |
Why?
|
| Rehabilitation, Vocational | 1 | 2005 | 34 | 0.260 |
Why?
|
| Internal Medicine | 5 | 2005 | 148 | 0.250 |
Why?
|
| Risk Factors | 16 | 2012 | 5015 | 0.250 |
Why?
|
| Health Surveys | 3 | 2006 | 306 | 0.250 |
Why?
|
| Cocaine-Related Disorders | 1 | 2006 | 75 | 0.250 |
Why?
|
| Patient Selection | 4 | 2024 | 446 | 0.250 |
Why?
|
| Ethanol | 1 | 2008 | 307 | 0.240 |
Why?
|
| United States Department of Veterans Affairs | 5 | 2014 | 513 | 0.240 |
Why?
|
| Drug Utilization | 2 | 2005 | 223 | 0.240 |
Why?
|
| Health Services for the Aged | 2 | 2004 | 48 | 0.240 |
Why?
|
| Mobile Health Units | 1 | 2024 | 10 | 0.240 |
Why?
|
| Surgery Department, Hospital | 2 | 1998 | 20 | 0.240 |
Why?
|
| Hospitals, Community | 2 | 2019 | 71 | 0.240 |
Why?
|
| Odds Ratio | 7 | 2014 | 773 | 0.230 |
Why?
|
| Motivational Interviewing | 2 | 2022 | 42 | 0.230 |
Why?
|
| Sex Factors | 7 | 2013 | 960 | 0.220 |
Why?
|
| Comprehensive Health Care | 1 | 2004 | 18 | 0.220 |
Why?
|
| Sex Work | 1 | 2023 | 21 | 0.220 |
Why?
|
| Insurance, Health | 1 | 2025 | 141 | 0.220 |
Why?
|
| Child | 4 | 2021 | 4304 | 0.220 |
Why?
|
| Seroepidemiologic Studies | 2 | 2023 | 48 | 0.220 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2023 | 97 | 0.220 |
Why?
|
| Health Behavior | 3 | 2002 | 473 | 0.220 |
Why?
|
| Medically Uninsured | 2 | 2019 | 40 | 0.210 |
Why?
|
| Disabled Persons | 1 | 2006 | 205 | 0.210 |
Why?
|
| Mental Processes | 1 | 2023 | 18 | 0.210 |
Why?
|
| Vascular Surgical Procedures | 4 | 1993 | 245 | 0.210 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2012 | 809 | 0.210 |
Why?
|
| Connecticut | 2 | 2013 | 86 | 0.210 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 71 | 0.200 |
Why?
|
| Preoperative Care | 4 | 2007 | 175 | 0.200 |
Why?
|
| Federal Government | 2 | 2017 | 20 | 0.200 |
Why?
|
| Prescription Drug Diversion | 1 | 2022 | 7 | 0.200 |
Why?
|
| Drug Utilization Review | 2 | 1999 | 56 | 0.200 |
Why?
|
| Mandatory Reporting | 1 | 2002 | 18 | 0.200 |
Why?
|
| Friends | 1 | 2022 | 29 | 0.190 |
Why?
|
| Vaccination | 1 | 2004 | 337 | 0.190 |
Why?
|
| Influenza, Human | 1 | 2004 | 193 | 0.190 |
Why?
|
| Domestic Violence | 1 | 2002 | 35 | 0.190 |
Why?
|
| Safe Sex | 1 | 2001 | 25 | 0.190 |
Why?
|
| Transportation of Patients | 1 | 2001 | 42 | 0.180 |
Why?
|
| Binge Drinking | 1 | 2021 | 29 | 0.180 |
Why?
|
| Guideline Adherence | 4 | 2014 | 296 | 0.180 |
Why?
|
| Hospitals, Teaching | 3 | 2002 | 103 | 0.180 |
Why?
|
| Health Services Research | 4 | 2013 | 270 | 0.180 |
Why?
|
| Medical History Taking | 1 | 2001 | 58 | 0.180 |
Why?
|
| Activities of Daily Living | 2 | 1999 | 298 | 0.180 |
Why?
|
| Endarterectomy | 4 | 1989 | 17 | 0.180 |
Why?
|
| Coercion | 2 | 2016 | 53 | 0.180 |
Why?
|
| Smoking | 3 | 2014 | 830 | 0.180 |
Why?
|
| Guilt | 1 | 2020 | 7 | 0.170 |
Why?
|
| Shame | 1 | 2020 | 8 | 0.170 |
Why?
|
| Cocaine | 4 | 2012 | 86 | 0.170 |
Why?
|
| Linear Models | 5 | 2012 | 422 | 0.170 |
Why?
|
| Judgment | 1 | 2020 | 30 | 0.170 |
Why?
|
| Mortality | 1 | 2001 | 159 | 0.170 |
Why?
|
| Needs Assessment | 1 | 2001 | 188 | 0.170 |
Why?
|
| Hospitals, Veterans | 2 | 2012 | 159 | 0.170 |
Why?
|
| Feasibility Studies | 5 | 2013 | 524 | 0.170 |
Why?
|
| Sickness Impact Profile | 1 | 1999 | 46 | 0.170 |
Why?
|
| Ambulatory Care Facilities | 1 | 2000 | 102 | 0.170 |
Why?
|
| Health Equity | 1 | 2020 | 42 | 0.170 |
Why?
|
| Vermont | 1 | 2019 | 17 | 0.170 |
Why?
|
| Emergencies | 2 | 1999 | 114 | 0.170 |
Why?
|
| Cost Allocation | 1 | 2019 | 3 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2024 | 1095 | 0.160 |
Why?
|
| New Hampshire | 1 | 2019 | 42 | 0.160 |
Why?
|
| Graft Survival | 2 | 2017 | 279 | 0.160 |
Why?
|
| Risk Assessment | 4 | 2011 | 1914 | 0.160 |
Why?
|
| Statistics as Topic | 4 | 2014 | 147 | 0.160 |
Why?
|
| Professional-Patient Relations | 1 | 2020 | 127 | 0.160 |
Why?
|
| Carotid Arteries | 2 | 1989 | 59 | 0.160 |
Why?
|
| Postpartum Period | 1 | 2021 | 203 | 0.160 |
Why?
|
| Medication Errors | 1 | 1999 | 116 | 0.160 |
Why?
|
| Pandemics | 2 | 2021 | 608 | 0.160 |
Why?
|
| AIDS-Related Opportunistic Infections | 2 | 1995 | 67 | 0.160 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 31 | 0.160 |
Why?
|
| Analysis of Variance | 8 | 2008 | 576 | 0.160 |
Why?
|
| Central Nervous System Stimulants | 2 | 2024 | 63 | 0.150 |
Why?
|
| Maternal Health Services | 1 | 2019 | 64 | 0.150 |
Why?
|
| Communication | 2 | 2023 | 554 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 160 | 0.150 |
Why?
|
| Focus Groups | 1 | 2020 | 291 | 0.150 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 3 | 2013 | 26 | 0.150 |
Why?
|
| Decision Making | 2 | 2019 | 390 | 0.150 |
Why?
|
| Health Insurance Exchanges | 1 | 2017 | 1 | 0.150 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 87 | 0.150 |
Why?
|
| Interprofessional Relations | 2 | 2012 | 131 | 0.150 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 1 | 1998 | 11 | 0.150 |
Why?
|
| Breast Feeding | 1 | 2020 | 138 | 0.150 |
Why?
|
| Pain Management | 1 | 2019 | 145 | 0.150 |
Why?
|
| Transportation | 3 | 2024 | 33 | 0.150 |
Why?
|
| Risk Management | 1 | 1998 | 39 | 0.150 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2021 | 249 | 0.150 |
Why?
|
| Polytetrafluoroethylene | 1 | 1997 | 18 | 0.140 |
Why?
|
| Psychotic Disorders | 2 | 2012 | 151 | 0.140 |
Why?
|
| Public Policy | 1 | 2018 | 41 | 0.140 |
Why?
|
| Cardiology | 2 | 1997 | 165 | 0.140 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2014 | 142 | 0.140 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 1998 | 195 | 0.140 |
Why?
|
| Patient Preference | 1 | 2018 | 76 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 187 | 0.140 |
Why?
|
| Patient Participation | 1 | 2019 | 211 | 0.140 |
Why?
|
| Donor Selection | 1 | 2017 | 16 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 199 | 0.140 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 1997 | 42 | 0.140 |
Why?
|
| Survival Rate | 3 | 2019 | 791 | 0.140 |
Why?
|
| Wounds and Injuries | 1 | 1999 | 237 | 0.140 |
Why?
|
| Urban Population | 7 | 2008 | 182 | 0.140 |
Why?
|
| Schizophrenia | 2 | 2012 | 256 | 0.140 |
Why?
|
| Patient Care Management | 1 | 2017 | 29 | 0.140 |
Why?
|
| Combined Modality Therapy | 5 | 1999 | 355 | 0.140 |
Why?
|
| Physician's Role | 1 | 1998 | 119 | 0.140 |
Why?
|
| Surgical Wound Infection | 1 | 1998 | 108 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2001 | 420 | 0.140 |
Why?
|
| Organizational Innovation | 1 | 2017 | 85 | 0.130 |
Why?
|
| Bipolar Disorder | 2 | 2012 | 254 | 0.130 |
Why?
|
| Cross Infection | 1 | 1998 | 151 | 0.130 |
Why?
|
| Diabetic Angiopathies | 3 | 2009 | 25 | 0.130 |
Why?
|
| Incidence | 5 | 2011 | 1237 | 0.130 |
Why?
|
| Chicago | 3 | 2001 | 24 | 0.130 |
Why?
|
| Organizations | 1 | 2016 | 6 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2017 | 134 | 0.130 |
Why?
|
| Social Support | 2 | 2013 | 358 | 0.130 |
Why?
|
| Biocompatible Materials | 1 | 1997 | 140 | 0.130 |
Why?
|
| Postoperative Care | 1 | 1996 | 112 | 0.130 |
Why?
|
| Diabetes Complications | 2 | 2011 | 102 | 0.130 |
Why?
|
| Human Experimentation | 1 | 2016 | 33 | 0.130 |
Why?
|
| Renal Dialysis | 1 | 1997 | 185 | 0.130 |
Why?
|
| Contract Services | 1 | 2015 | 2 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 299 | 0.130 |
Why?
|
| Endarterectomy, Carotid | 1 | 1996 | 87 | 0.130 |
Why?
|
| Patient Education as Topic | 3 | 2014 | 446 | 0.130 |
Why?
|
| Neovascularization, Pathologic | 2 | 1995 | 138 | 0.120 |
Why?
|
| Patient Admission | 1 | 2017 | 185 | 0.120 |
Why?
|
| Methylprednisolone | 1 | 1995 | 31 | 0.120 |
Why?
|
| Risk Reduction Behavior | 2 | 2006 | 125 | 0.120 |
Why?
|
| Body Weight | 1 | 2017 | 378 | 0.120 |
Why?
|
| Intersectoral Collaboration | 1 | 2015 | 17 | 0.120 |
Why?
|
| Carcinoma | 2 | 1987 | 117 | 0.120 |
Why?
|
| Spinal Cord Injuries | 1 | 1995 | 38 | 0.120 |
Why?
|
| Community-Institutional Relations | 1 | 2015 | 37 | 0.120 |
Why?
|
| Fibroblast Growth Factors | 1 | 1995 | 63 | 0.120 |
Why?
|
| Survival Analysis | 4 | 2012 | 553 | 0.120 |
Why?
|
| Safety-net Providers | 1 | 2015 | 34 | 0.120 |
Why?
|
| Taurine | 1 | 2014 | 5 | 0.120 |
Why?
|
| Disulfiram | 1 | 2014 | 4 | 0.120 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 1996 | 137 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2017 | 266 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2014 | 19 | 0.120 |
Why?
|
| Directive Counseling | 1 | 2014 | 39 | 0.120 |
Why?
|
| Elective Surgical Procedures | 2 | 2022 | 104 | 0.120 |
Why?
|
| Aftercare | 2 | 2022 | 67 | 0.120 |
Why?
|
| Clinical Trials as Topic | 1 | 2017 | 442 | 0.110 |
Why?
|
| Spinal Cord | 1 | 1995 | 197 | 0.110 |
Why?
|
| Accountable Care Organizations | 1 | 2015 | 57 | 0.110 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 694 | 0.110 |
Why?
|
| Housing | 2 | 2024 | 72 | 0.110 |
Why?
|
| Smoking Prevention | 2 | 2013 | 162 | 0.110 |
Why?
|
| Smoke-Free Policy | 1 | 2013 | 9 | 0.110 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2014 | 63 | 0.110 |
Why?
|
| Staff Development | 2 | 2007 | 56 | 0.110 |
Why?
|
| History, 19th Century | 3 | 2001 | 42 | 0.110 |
Why?
|
| Tobacco Products | 1 | 2014 | 75 | 0.110 |
Why?
|
| Ribavirin | 1 | 2013 | 24 | 0.110 |
Why?
|
| Education, Pharmacy, Continuing | 1 | 2013 | 3 | 0.110 |
Why?
|
| Diffusion of Innovation | 1 | 2013 | 56 | 0.110 |
Why?
|
| Personal Autonomy | 1 | 2013 | 66 | 0.110 |
Why?
|
| Interferon-alpha | 1 | 2013 | 98 | 0.110 |
Why?
|
| Collateral Circulation | 1 | 1992 | 22 | 0.100 |
Why?
|
| Viral Load | 1 | 2013 | 229 | 0.100 |
Why?
|
| History, 20th Century | 3 | 2001 | 225 | 0.100 |
Why?
|
| Specialization | 2 | 2005 | 73 | 0.100 |
Why?
|
| Electronic Prescribing | 1 | 2012 | 11 | 0.100 |
Why?
|
| Physician-Patient Relations | 3 | 2002 | 388 | 0.100 |
Why?
|
| Polyethylene Glycols | 1 | 2013 | 162 | 0.100 |
Why?
|
| Program Development | 3 | 2008 | 210 | 0.100 |
Why?
|
| Administration, Oral | 1 | 2013 | 344 | 0.100 |
Why?
|
| Total Quality Management | 1 | 1992 | 58 | 0.100 |
Why?
|
| Blood Coagulation | 1 | 2012 | 50 | 0.100 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2011 | 3 | 0.090 |
Why?
|
| Cause of Death | 1 | 2012 | 200 | 0.090 |
Why?
|
| Lacerations | 1 | 2011 | 16 | 0.090 |
Why?
|
| Interview, Psychological | 2 | 2009 | 77 | 0.090 |
Why?
|
| Tuberculosis | 3 | 2000 | 262 | 0.090 |
Why?
|
| Intensive Care Units | 2 | 1996 | 449 | 0.090 |
Why?
|
| Mandatory Programs | 1 | 2011 | 19 | 0.090 |
Why?
|
| Reproducibility of Results | 4 | 2013 | 1551 | 0.090 |
Why?
|
| Adenocarcinoma | 2 | 1988 | 323 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2014 | 846 | 0.090 |
Why?
|
| Vitreous Body | 1 | 2011 | 31 | 0.090 |
Why?
|
| Cataract | 1 | 2011 | 54 | 0.090 |
Why?
|
| Accreditation | 2 | 2007 | 69 | 0.090 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2008 | 123 | 0.090 |
Why?
|
| Hospital Departments | 1 | 1990 | 13 | 0.090 |
Why?
|
| Crack Cocaine | 3 | 1997 | 7 | 0.090 |
Why?
|
| Streptonigrin | 1 | 2010 | 3 | 0.090 |
Why?
|
| Erectile Dysfunction | 1 | 2010 | 22 | 0.090 |
Why?
|
| Hospitals, University | 2 | 2001 | 50 | 0.090 |
Why?
|
| Health Status Disparities | 1 | 2012 | 147 | 0.090 |
Why?
|
| Citalopram | 1 | 2010 | 17 | 0.090 |
Why?
|
| Heart Failure | 2 | 2014 | 867 | 0.090 |
Why?
|
| Socioeconomic Factors | 4 | 2019 | 781 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2010 | 680 | 0.090 |
Why?
|
| Postoperative Period | 1 | 2010 | 125 | 0.090 |
Why?
|
| Medicine | 1 | 1990 | 56 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 900 | 0.090 |
Why?
|
| Testosterone | 1 | 2010 | 111 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 282 | 0.090 |
Why?
|
| Periodicals as Topic | 1 | 2012 | 173 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2012 | 220 | 0.080 |
Why?
|
| Tuberculin Test | 2 | 2000 | 10 | 0.080 |
Why?
|
| Models, Organizational | 3 | 2015 | 92 | 0.080 |
Why?
|
| Long-Term Care | 1 | 2010 | 174 | 0.080 |
Why?
|
| Appointments and Schedules | 1 | 2009 | 53 | 0.080 |
Why?
|
| Unsafe Sex | 1 | 2009 | 27 | 0.080 |
Why?
|
| Monitoring, Physiologic | 1 | 1990 | 150 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2012 | 673 | 0.080 |
Why?
|
| Hemodynamics | 1 | 1990 | 236 | 0.080 |
Why?
|
| Skin | 3 | 2006 | 353 | 0.080 |
Why?
|
| Inactivation, Metabolic | 1 | 2008 | 13 | 0.080 |
Why?
|
| Macular Degeneration | 1 | 2011 | 176 | 0.080 |
Why?
|
| New York City | 9 | 2000 | 75 | 0.080 |
Why?
|
| Internal-External Control | 1 | 2008 | 32 | 0.070 |
Why?
|
| Verbal Behavior | 1 | 2008 | 37 | 0.070 |
Why?
|
| AIDS Serodiagnosis | 2 | 2002 | 19 | 0.070 |
Why?
|
| Antisocial Personality Disorder | 1 | 2008 | 35 | 0.070 |
Why?
|
| HIV Seroprevalence | 3 | 1996 | 7 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 1988 | 56 | 0.070 |
Why?
|
| Societies, Medical | 2 | 2001 | 330 | 0.070 |
Why?
|
| Blood Gas Monitoring, Transcutaneous | 2 | 2000 | 4 | 0.070 |
Why?
|
| Intestine, Large | 1 | 1987 | 5 | 0.070 |
Why?
|
| Life Tables | 2 | 1997 | 24 | 0.070 |
Why?
|
| Cost Control | 1 | 2007 | 23 | 0.070 |
Why?
|
| Community Networks | 1 | 2007 | 29 | 0.070 |
Why?
|
| Clinical Competence | 3 | 2002 | 678 | 0.070 |
Why?
|
| Professional Practice | 1 | 2006 | 22 | 0.070 |
Why?
|
| Educational Status | 1 | 2008 | 271 | 0.070 |
Why?
|
| Drug Prescriptions | 2 | 2006 | 188 | 0.070 |
Why?
|
| Risk | 1 | 2007 | 372 | 0.070 |
Why?
|
| Rabbits | 2 | 2000 | 330 | 0.070 |
Why?
|
| Confidence Intervals | 2 | 2011 | 256 | 0.070 |
Why?
|
| Drug Interactions | 2 | 2012 | 115 | 0.070 |
Why?
|
| Medical Records | 1 | 2006 | 138 | 0.070 |
Why?
|
| Organizational Culture | 1 | 2007 | 112 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 36 | 0.070 |
Why?
|
| Eligibility Determination | 1 | 2006 | 34 | 0.070 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2006 | 8 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 196 | 0.060 |
Why?
|
| Confidentiality | 2 | 2003 | 52 | 0.060 |
Why?
|
| Cues | 1 | 2006 | 76 | 0.060 |
Why?
|
| Medical Audit | 1 | 2006 | 60 | 0.060 |
Why?
|
| Attitude to Health | 1 | 2008 | 275 | 0.060 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2006 | 51 | 0.060 |
Why?
|
| Rats, Sprague-Dawley | 2 | 1998 | 570 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2017 | 387 | 0.060 |
Why?
|
| Sleep Stages | 1 | 2005 | 16 | 0.060 |
Why?
|
| Injections | 2 | 2018 | 79 | 0.060 |
Why?
|
| Arterial Occlusive Diseases | 2 | 1976 | 68 | 0.060 |
Why?
|
| Specialties, Surgical | 2 | 1999 | 44 | 0.060 |
Why?
|
| Depression | 2 | 2010 | 857 | 0.060 |
Why?
|
| Plant Preparations | 1 | 2005 | 16 | 0.060 |
Why?
|
| Women's Health | 1 | 2008 | 390 | 0.060 |
Why?
|
| Gynecology | 2 | 2005 | 52 | 0.060 |
Why?
|
| Mucin-1 | 1 | 2004 | 14 | 0.060 |
Why?
|
| Epidermolysis Bullosa | 1 | 2004 | 10 | 0.060 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2009 | 78 | 0.060 |
Why?
|
| Disability Evaluation | 1 | 2006 | 216 | 0.060 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2005 | 47 | 0.060 |
Why?
|
| Muscle, Skeletal | 2 | 2000 | 674 | 0.060 |
Why?
|
| Sleep Apnea Syndromes | 1 | 2005 | 27 | 0.060 |
Why?
|
| Femoral Artery | 3 | 1988 | 93 | 0.060 |
Why?
|
| Cannabinoids | 1 | 2005 | 35 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 1996 | 301 | 0.060 |
Why?
|
| Gender Identity | 1 | 2025 | 61 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2005 | 52 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2024 | 66 | 0.060 |
Why?
|
| Hepatitis C Antibodies | 1 | 2024 | 8 | 0.060 |
Why?
|
| Popliteal Artery | 2 | 1976 | 25 | 0.060 |
Why?
|
| Cannabis | 1 | 2005 | 47 | 0.060 |
Why?
|
| Decision Trees | 1 | 2003 | 51 | 0.060 |
Why?
|
| Obstetrics | 2 | 2005 | 85 | 0.060 |
Why?
|
| Uncompensated Care | 1 | 2003 | 5 | 0.050 |
Why?
|
| Refusal to Treat | 1 | 2003 | 3 | 0.050 |
Why?
|
| Laboratories, Hospital | 1 | 2003 | 9 | 0.050 |
Why?
|
| Halfway Houses | 1 | 2003 | 2 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2003 | 74 | 0.050 |
Why?
|
| Sexual and Gender Minorities | 1 | 2025 | 73 | 0.050 |
Why?
|
| Waiting Lists | 1 | 2003 | 48 | 0.050 |
Why?
|
| Rats | 2 | 1998 | 1912 | 0.050 |
Why?
|
| Attitude | 1 | 2023 | 100 | 0.050 |
Why?
|
| Convalescence | 1 | 2003 | 17 | 0.050 |
Why?
|
| Schools, Medical | 2 | 2001 | 144 | 0.050 |
Why?
|
| Community Mental Health Centers | 1 | 2003 | 18 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2011 | 1449 | 0.050 |
Why?
|
| House Calls | 1 | 2023 | 18 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2006 | 258 | 0.050 |
Why?
|
| Phylogeny | 1 | 2024 | 332 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2004 | 353 | 0.050 |
Why?
|
| Coronary Artery Disease | 1 | 2006 | 277 | 0.050 |
Why?
|
| Occupational Health Services | 1 | 2003 | 39 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 674 | 0.050 |
Why?
|
| Managed Care Programs | 1 | 2003 | 93 | 0.050 |
Why?
|
| Grounded Theory | 1 | 2022 | 15 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2004 | 277 | 0.050 |
Why?
|
| Habits | 1 | 2022 | 21 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2004 | 233 | 0.050 |
Why?
|
| Interpersonal Relations | 2 | 2001 | 150 | 0.050 |
Why?
|
| Parenting | 1 | 2023 | 73 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2003 | 161 | 0.050 |
Why?
|
| Workplace | 1 | 2003 | 180 | 0.050 |
Why?
|
| Curriculum | 1 | 2005 | 550 | 0.050 |
Why?
|
| Crisis Intervention | 1 | 2002 | 28 | 0.050 |
Why?
|
| Animals | 6 | 2000 | 19648 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2002 | 134 | 0.050 |
Why?
|
| Hospitals, Urban | 1 | 2001 | 44 | 0.050 |
Why?
|
| Episode of Care | 1 | 2001 | 9 | 0.050 |
Why?
|
| Poverty Areas | 1 | 2001 | 16 | 0.050 |
Why?
|
| Genomics | 1 | 2024 | 314 | 0.050 |
Why?
|
| Poverty | 1 | 2003 | 286 | 0.050 |
Why?
|
| Specialty Boards | 2 | 1990 | 12 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 314 | 0.040 |
Why?
|
| Factor Analysis, Statistical | 2 | 2013 | 104 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 1996 | 454 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2001 | 113 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2000 | 108 | 0.040 |
Why?
|
| Certification | 2 | 1990 | 49 | 0.040 |
Why?
|
| Quality Indicators, Health Care | 2 | 2014 | 328 | 0.040 |
Why?
|
| Cardiac Rehabilitation | 1 | 2021 | 67 | 0.040 |
Why?
|
| Nurses | 1 | 2021 | 103 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2002 | 203 | 0.040 |
Why?
|
| Peptic Ulcer | 1 | 1999 | 21 | 0.040 |
Why?
|
| Research Design | 3 | 2011 | 565 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 1996 | 79 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 1999 | 35 | 0.040 |
Why?
|
| Histamine Antagonists | 1 | 1999 | 5 | 0.040 |
Why?
|
| Psychometrics | 2 | 2014 | 356 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 249 | 0.040 |
Why?
|
| Morbidity | 1 | 1999 | 109 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2004 | 404 | 0.040 |
Why?
|
| Diabetes Mellitus | 2 | 2006 | 537 | 0.040 |
Why?
|
| Physicians | 2 | 2021 | 436 | 0.040 |
Why?
|
| Perioperative Period | 1 | 2019 | 20 | 0.040 |
Why?
|
| Streptozocin | 1 | 1998 | 20 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 479 | 0.040 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1998 | 8 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 1998 | 73 | 0.040 |
Why?
|
| Accidental Falls | 1 | 1999 | 145 | 0.040 |
Why?
|
| Self-Help Groups | 1 | 1998 | 37 | 0.040 |
Why?
|
| Income | 1 | 2019 | 160 | 0.040 |
Why?
|
| Forearm | 1 | 1997 | 19 | 0.040 |
Why?
|
| AIDS Vaccines | 1 | 1997 | 67 | 0.040 |
Why?
|
| Residence Characteristics | 2 | 2015 | 224 | 0.040 |
Why?
|
| Angiography | 2 | 1974 | 145 | 0.030 |
Why?
|
| Vascular Patency | 1 | 1997 | 134 | 0.030 |
Why?
|
| Benchmarking | 1 | 1998 | 135 | 0.030 |
Why?
|
| Radioisotope Teletherapy | 1 | 1996 | 1 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 1995 | 2069 | 0.030 |
Why?
|
| Cobalt Radioisotopes | 1 | 1996 | 5 | 0.030 |
Why?
|
| Spermatozoa | 1 | 1998 | 251 | 0.030 |
Why?
|
| Thailand | 5 | 1995 | 94 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 1999 | 306 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 104 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1996 | 61 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 1997 | 66 | 0.030 |
Why?
|
| Mental Health | 1 | 1999 | 348 | 0.030 |
Why?
|
| Condoms | 2 | 1993 | 47 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 1996 | 35 | 0.030 |
Why?
|
| Angina Pectoris | 1 | 1996 | 36 | 0.030 |
Why?
|
| Heroin | 2 | 1997 | 12 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1978 | 213 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1997 | 120 | 0.030 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 1995 | 4 | 0.030 |
Why?
|
| Saphenous Vein | 2 | 1976 | 43 | 0.030 |
Why?
|
| Spinal Puncture | 1 | 1995 | 13 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 1996 | 233 | 0.030 |
Why?
|
| Safety | 1 | 1996 | 141 | 0.030 |
Why?
|
| Economic Competition | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 1996 | 68 | 0.030 |
Why?
|
| Ownership | 1 | 2015 | 17 | 0.030 |
Why?
|
| Systems Integration | 1 | 2015 | 27 | 0.030 |
Why?
|
| Behavior | 1 | 1995 | 38 | 0.030 |
Why?
|
| Drug Synergism | 1 | 1995 | 133 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 1998 | 1063 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 1995 | 179 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 1995 | 77 | 0.030 |
Why?
|
| Coronary Disease | 1 | 1996 | 250 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 1995 | 133 | 0.030 |
Why?
|
| Blood Vessel Prosthesis | 2 | 1976 | 209 | 0.030 |
Why?
|
| Movement | 1 | 1995 | 146 | 0.030 |
Why?
|
| Coronary Artery Bypass | 1 | 1996 | 274 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1995 | 436 | 0.030 |
Why?
|
| Hospitals | 1 | 1997 | 376 | 0.030 |
Why?
|
| History, 18th Century | 1 | 1993 | 8 | 0.030 |
Why?
|
| History, Ancient | 1 | 1993 | 11 | 0.030 |
Why?
|
| Health Facility Administrators | 1 | 2013 | 7 | 0.030 |
Why?
|
| Motivation | 1 | 2016 | 266 | 0.030 |
Why?
|
| Didanosine | 1 | 1992 | 3 | 0.030 |
Why?
|
| Zidovudine | 1 | 1992 | 12 | 0.030 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2014 | 160 | 0.030 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 1993 | 71 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 1992 | 15 | 0.030 |
Why?
|
| Spectrophotometry | 1 | 1992 | 31 | 0.030 |
Why?
|
| Ligation | 1 | 1992 | 35 | 0.030 |
Why?
|
| Washington | 1 | 2012 | 25 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2014 | 263 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 94 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2012 | 140 | 0.030 |
Why?
|
| Prothrombin Time | 1 | 2012 | 6 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2012 | 8 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 352 | 0.020 |
Why?
|
| Contrast Media | 1 | 1974 | 410 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 1985 | 71 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2012 | 70 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2012 | 57 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2012 | 91 | 0.020 |
Why?
|
| Health Status Indicators | 1 | 2012 | 98 | 0.020 |
Why?
|
| Medical Staff, Hospital | 1 | 1992 | 59 | 0.020 |
Why?
|
| Health Education | 2 | 2008 | 184 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1990 | 24 | 0.020 |
Why?
|
| Radiography | 1 | 1992 | 506 | 0.020 |
Why?
|
| Cardiac Output | 1 | 1990 | 34 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 1990 | 44 | 0.020 |
Why?
|
| Acute Disease | 1 | 1992 | 659 | 0.020 |
Why?
|
| Surgery, Plastic | 1 | 1990 | 13 | 0.020 |
Why?
|
| Hypertension | 1 | 1996 | 601 | 0.020 |
Why?
|
| Teaching | 1 | 1990 | 154 | 0.020 |
Why?
|
| Thoracic Surgery | 1 | 1990 | 66 | 0.020 |
Why?
|
| National Institute on Drug Abuse (U.S.) | 1 | 2009 | 2 | 0.020 |
Why?
|
| Coumarins | 1 | 1988 | 7 | 0.020 |
Why?
|
| HIV-1 | 1 | 1994 | 708 | 0.020 |
Why?
|
| Educational Measurement | 1 | 1990 | 207 | 0.020 |
Why?
|
| Iodine Isotopes | 1 | 1968 | 2 | 0.020 |
Why?
|
| Hyperthyroidism | 1 | 1968 | 17 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 1988 | 72 | 0.020 |
Why?
|
| Financial Support | 1 | 2008 | 4 | 0.020 |
Why?
|
| Necrosis | 1 | 1988 | 138 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 1988 | 53 | 0.020 |
Why?
|
| Predictive Value of Tests | 2 | 2003 | 1031 | 0.020 |
Why?
|
| Psychology | 1 | 2008 | 47 | 0.020 |
Why?
|
| Renal Veins | 1 | 1987 | 6 | 0.020 |
Why?
|
| Heparin | 1 | 1988 | 113 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 178 | 0.020 |
Why?
|
| Pediatrics | 1 | 1990 | 266 | 0.020 |
Why?
|
| Lipids | 1 | 2009 | 306 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 1987 | 59 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2009 | 204 | 0.020 |
Why?
|
| Surgical Staplers | 1 | 1987 | 6 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 1988 | 97 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 1988 | 196 | 0.020 |
Why?
|
| Arteriovenous Fistula | 1 | 1987 | 39 | 0.020 |
Why?
|
| Colostomy | 1 | 1987 | 23 | 0.020 |
Why?
|
| Health Promotion | 1 | 2011 | 491 | 0.020 |
Why?
|
| Universities | 1 | 2008 | 152 | 0.020 |
Why?
|
| Suture Techniques | 1 | 1987 | 84 | 0.020 |
Why?
|
| Celecoxib | 1 | 2006 | 14 | 0.020 |
Why?
|
| England | 1 | 2006 | 21 | 0.020 |
Why?
|
| Lactones | 1 | 2006 | 25 | 0.020 |
Why?
|
| Sulfones | 1 | 2006 | 37 | 0.020 |
Why?
|
| Cholesterol, HDL | 1 | 2006 | 78 | 0.020 |
Why?
|
| Students | 1 | 2008 | 207 | 0.020 |
Why?
|
| Dogs | 1 | 1987 | 317 | 0.020 |
Why?
|
| Cholesterol, LDL | 1 | 2006 | 105 | 0.020 |
Why?
|
| Permissiveness | 1 | 2005 | 1 | 0.020 |
Why?
|
| Pyridines | 1 | 2006 | 98 | 0.020 |
Why?
|
| Leg | 2 | 1976 | 83 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2006 | 74 | 0.020 |
Why?
|
| American Heart Association | 1 | 2006 | 128 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2006 | 123 | 0.020 |
Why?
|
| Bowen's Disease | 1 | 2004 | 1 | 0.010 |
Why?
|
| Morals | 1 | 2005 | 22 | 0.010 |
Why?
|
| Brazil | 2 | 1995 | 86 | 0.010 |
Why?
|
| Radiotherapy | 1 | 1985 | 63 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2004 | 104 | 0.010 |
Why?
|
| Glycosylation | 1 | 2004 | 134 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2004 | 125 | 0.010 |
Why?
|
| Blood Pressure | 1 | 2006 | 522 | 0.010 |
Why?
|
| Information Services | 1 | 2002 | 34 | 0.010 |
Why?
|
| Social Perception | 1 | 2002 | 36 | 0.010 |
Why?
|
| Body Mass Index | 1 | 2006 | 886 | 0.010 |
Why?
|
| Boston | 1 | 2002 | 331 | 0.010 |
Why?
|
| Biomarkers | 1 | 2006 | 1210 | 0.010 |
Why?
|
| Learning | 1 | 2000 | 171 | 0.010 |
Why?
|
| Sigmoid Neoplasms | 1 | 1978 | 2 | 0.010 |
Why?
|
| Illinois | 1 | 1997 | 14 | 0.010 |
Why?
|
| Skin Tests | 1 | 1997 | 21 | 0.010 |
Why?
|
| Hospital Charges | 1 | 1997 | 23 | 0.010 |
Why?
|
| Marijuana Smoking | 1 | 1997 | 16 | 0.010 |
Why?
|
| World Health Organization | 1 | 1996 | 31 | 0.010 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1995 | 28 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1976 | 118 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 1976 | 223 | 0.010 |
Why?
|
| Scotland | 1 | 1995 | 7 | 0.010 |
Why?
|
| Fever | 1 | 1995 | 63 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 1995 | 34 | 0.010 |
Why?
|
| Graft Rejection | 1 | 1976 | 259 | 0.010 |
Why?
|
| Self-Assessment | 1 | 1994 | 54 | 0.010 |
Why?
|
| Personality Development | 1 | 1993 | 6 | 0.010 |
Why?
|
| Child Abuse, Sexual | 1 | 1993 | 21 | 0.010 |
Why?
|
| Child of Impaired Parents | 1 | 1993 | 28 | 0.010 |
Why?
|
| Dangerous Behavior | 1 | 1993 | 22 | 0.010 |
Why?
|
| Methods | 1 | 1972 | 39 | 0.010 |
Why?
|
| Rehabilitation | 1 | 1991 | 6 | 0.010 |
Why?
|
| Mycobacterium tuberculosis | 1 | 1995 | 383 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 1972 | 205 | 0.010 |
Why?
|
| Contraception | 1 | 1992 | 64 | 0.010 |
Why?
|
| Prenatal Care | 1 | 1993 | 180 | 0.010 |
Why?
|
| Polymers | 1 | 1972 | 316 | 0.000 |
Why?
|
| Aorta, Thoracic | 1 | 1988 | 78 | 0.000 |
Why?
|
| Intermittent Claudication | 1 | 1988 | 48 | 0.000 |
Why?
|
| Aorta | 1 | 1988 | 106 | 0.000 |
Why?
|
| Hypothyroidism | 1 | 1968 | 39 | 0.000 |
Why?
|
| Aortic Aneurysm | 1 | 1987 | 84 | 0.000 |
Why?
|